Info

A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company’s lead product candidate, APF530, is in a pivotal Phase III clinical trial for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management. The Company has several additional product candidates using its Biochronomer technology in early stages of development, including APF328 and APF505.(Source: 10-K)